Testosterone therapy is a medical treatment designed to boost the levels of testosterone in men who have low levels of the hormone. Testosterone is an important hormone that plays a crucial role in the development and maintenance of male characteristics such as muscle mass, bone density, and sexual function. Low levels of testosterone can cause a range of symptoms and health issues, including decreased libido, fatigue, depression, and decreased bone density.
There are several benefits associated with testosterone therapy for men with low testosterone levels:
Testosterone is important for cognitive function, including memory, attention, and spatial ability. Testosterone therapy can help improve cognitive function in men with low levels of testosterone.
It’s important to note that testosterone therapy may not be suitable for everyone. Men with prostate cancer or breast cancer, high red blood cell counts, or a history of blood clots should not receive testosterone therapy. It’s important to speak with a healthcare provider to determine if testosterone therapy is right for you.
– Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clinical Obesity. 2013;3(3-4):73-83. doi: 10.1111/cob.12026.
– Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism. J Cardiovasc Pharmacol Ther. 2017;22(4):414-433. doi: 10.1177/1074248416683167.
– Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi: 10.1210/jc.2018-00229.
– Huo S, Scialli AR, McGarvey S, et al. Treatment of men for “low testosterone”: a systematic review. PLoS One. 2016;11(9):e0162480. doi: 10.1371/journal.pone.0162480.
– Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165(5):687-701. doi: 10.1530/EJE-11-0462.